Feed aggregator

Now Is the Time to Buy Alternative Funds

Top Stories - Thu, 02/19/2026 - 03:00

Repsol Lifts Dividend, Maintains Buyback Pace

Top Stories - Thu, 02/19/2026 - 02:54

HUMAIN takes minority stake in xAI with $3bn investment

Top Stories - Thu, 02/19/2026 - 02:52

Google, Shopee-owner Sea to develop AI tools for e-commerce, gaming

Top Stories - Thu, 02/19/2026 - 02:36

What's a Retirement Budget at 65 With $1.2M and $2,900 Monthly Social Security?

Top Stories - Thu, 02/19/2026 - 02:00

Reliance, Adani drive India's AI push with plans to invest $210 billion

Top Stories - Thu, 02/19/2026 - 01:35

Hotel group Accor narrowly beats profit expectations in 2025

Top Stories - Thu, 02/19/2026 - 01:34

Why Paychex, Inc. (PAYX) Is Near Lows

Top Stories - Thu, 02/19/2026 - 00:43

Palantir Technologies Inc. (PLTR) Extends Airbus Deal, What It Means

Top Stories - Thu, 02/19/2026 - 00:43

Fortinet, Inc. (FTNT) Gets Price Target Boosts, Here’s Why

Top Stories - Thu, 02/19/2026 - 00:43

Why Wall Street Is Split on Joint Stock Company Kaspi.kz (KSPI) Right Now

Top Stories - Thu, 02/19/2026 - 00:43

Intuit Targets $2 Trillion Construction Market With New AI Suite

Top Stories - Thu, 02/19/2026 - 00:43

Why Wall Street Is Turning Cautious on Adobe Inc. (ADBE)

Top Stories - Thu, 02/19/2026 - 00:42

Is Microsoft Corporation (MSFT) The Most Profitable Software Stock to Buy Now?

Top Stories - Thu, 02/19/2026 - 00:42

India's Tata signs up OpenAI as customer for data centre business

Top Stories - Wed, 02/18/2026 - 22:02

Kirin's Yoshimura on Health Science Business Strategy

Top Stories - Wed, 02/18/2026 - 21:41

What I'm Watching With CubeSmart Stock To See If It Beats The Market

Top Stories - Wed, 02/18/2026 - 21:35

Evercore Notes AbbVie Inc.’s (ABBV) Tremfya Gains Market Share, But Future Earnings Growth May Be Limited

Top Stories - Wed, 02/18/2026 - 21:33

Needham Bullish on Neurocrine Biosciences, Inc. (NBIX) Pipeline Amid 2026 Growth Expectations for Crenessity and Ingrezza

Top Stories - Wed, 02/18/2026 - 21:33

Jefferies Assigns 65–75% Probability of Best-in-Class Efficacy for Definium Therapeutics, Inc.’s (DFTX) DT120 in Phase III

Top Stories - Wed, 02/18/2026 - 21:32
Syndicate content
 
Worldstockexchange® Information Center